Aluda Pharmaceuticals
Aluda Pharmaceuticals is dedicated to developing innovative drug discovery approaches targeting complex and evasive diseases, especially severe immune and fibrotic conditions. They focus on novel targets with holistic roles in disease progression, utilizing state-of-the-art tools like CRISPR, proteomic analysis, and phenotypic screening. Their mission is to address the limitations of existing treatments by discovering new drug molecules that can intervene in the complex biology of diseases such as fibrosis, cancer, and autoimmune disorders.
Industries
Nr. of Employees
small (1-50)
Aluda Pharmaceuticals
Menlo Park, California, United States, North America
Patents
2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
US-11390591-B2
View Details2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
US-10611736-B2
View Details
2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
US-11390591-B2
View Details2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
US-10611736-B2
View DetailsProducts
Vimentin-targeting small-molecule therapeutic candidate
Orally bioavailable small-molecule series that bind vimentin to modulate filament conformation and reduce pathological vimentin-enabled interactions. Preclinical data indicate activity in fibrosis (lung and liver), multiple autoimmune models via Treg activation, antiviral models including SARS-CoV-2, and tumor biology via exosome release inhibition.
STAT3-selective small-molecule series
A series of novel small molecules that selectively modulate STAT3 variants, developed as activators for anti-cancer immune strategies and as inhibitors for Th17-driven autoimmune diseases.
Vimentin-targeting small-molecule therapeutic candidate
Orally bioavailable small-molecule series that bind vimentin to modulate filament conformation and reduce pathological vimentin-enabled interactions. Preclinical data indicate activity in fibrosis (lung and liver), multiple autoimmune models via Treg activation, antiviral models including SARS-CoV-2, and tumor biology via exosome release inhibition.
STAT3-selective small-molecule series
A series of novel small molecules that selectively modulate STAT3 variants, developed as activators for anti-cancer immune strategies and as inhibitors for Th17-driven autoimmune diseases.
Services
Licensing and partnering of preclinical programs to external clinical development partners for late-stage development and commercialization.
Licensing and partnering of preclinical programs to external clinical development partners for late-stage development and commercialization.
Expertise Areas
- Preclinical pharmacology and in vivo disease modeling
- Small-molecule drug discovery and medicinal chemistry
- Phenotypic screening and target discovery
- Immunomodulation via regulatory T cell activation
Key Technologies
- Phenotypic screening
- CRISPR-based genetic screens
- Proteomic array analysis
- Large-scale data analytics / big data